Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCHER 1050: Dacomitinib vs Gefitinib in EGFR-mutant NSCLC
NCT01774721Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2013
- Primary completion
- Jul 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Started May 2013; status: completed.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01774721.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01774721.